Zhu Kangwei, Xia Yuren, Tian Xindi, He Yuchao, Zhou Jun, Han Ruyu, Guo Hua, Song Tianqiang, Chen Lu, Tian Xiangdong
Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Department of Biofunction Research, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU), Chiyoda, Japan.
Front Genet. 2023 Sep 8;14:1271381. doi: 10.3389/fgene.2023.1271381. eCollection 2023.
Cancer is a major public health issue globally and is one of the leading causes of death. Although available treatments improve the survival rate of some cases, many advanced tumors are insensitive to these treatments. Cancer cell differentiation reverts the malignant phenotype to its original state and may even induce differentiation into cell types found in other tissues. Leveraging differentiation-inducing therapy in high-grade tumor masses offers a less aggressive strategy to curb tumor progression and heightens chemotherapy sensitivity. Differentiation-inducing therapy has been demonstrated to be effective in a variety of tumor cells. For example, differentiation therapy has become the first choice for acute promyelocytic leukemia, with the cure rate of more than 90%. Although an appealing concept, the mechanism and clinical drugs used in differentiation therapy are still in their nascent stage, warranting further investigation. In this review, we examine the current differentiation-inducing therapeutic approach and discuss the clinical applications as well as the underlying biological basis of differentiation-inducing agents.
癌症是全球主要的公共卫生问题，也是主要死因之一。尽管现有治疗方法提高了部分病例的生存率，但许多晚期肿瘤对这些治疗不敏感。癌细胞分化可使恶性表型恢复到原始状态，甚至可能诱导分化为其他组织中发现的细胞类型。在高级别肿瘤块中利用诱导分化疗法提供了一种侵袭性较小的策略来抑制肿瘤进展并提高化疗敏感性。诱导分化疗法已被证明在多种肿瘤细胞中有效。例如，分化疗法已成为急性早幼粒细胞白血病的首选治疗方法，治愈率超过90%。尽管诱导分化疗法是一个很有吸引力的概念，但其作用机制和临床用药仍处于起步阶段，有待进一步研究。在本综述中，我们研究了当前的诱导分化治疗方法，并讨论了其临床应用以及诱导分化剂的潜在生物学基础。
